Can Engineered “Designer” T Cells Outsmart Chronic Hepatitis B?
Hepatitis Research and Treatment · 2010
DOI: 10.1155/2010/901216 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatitis Research and Treatment, 2010. Verfasst von U Protzer und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institut für Virologie, Technische Universität München/Helmholtz Zentrum München, 81675 München, Germany. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Deutsche Forschungsgemeinschaft, European Commission.
Abstract (Originalsprache)
More than 350 million people worldwide are persistently infected with human heptatitis B virus (HBV) and at risk to develop liver cirrhosis and hepatocellular carcinoma making long-term treatment necessary. While a vaccine is available and new antiviral drugs are being developed, elimination of persistently infected cells is still a major issue. Recent efforts in adoptive cell therapy are experimentally exploring immunotherapeutic elimination of HBV-infected cells by means of a biological attack with genetically engineered “designer” T cells.
Autor:innen und Institutionen
- Institut für Virologie, Technische Universität München/Helmholtz Zentrum München, 81675 München, Germany.
Förderung
- Deutsche Forschungsgemeinschaft
- European Commission
Zitieren
APA
Protzer, U., & Abken, H. (2010). Can Engineered “Designer” T Cells Outsmart Chronic Hepatitis B?. Hepatitis Research and Treatment. https://doi.org/10.1155/2010/901216
Vancouver
Protzer U, Abken H. Can Engineered “Designer” T Cells Outsmart Chronic Hepatitis B?. Hepatitis Research and Treatment. 2010. doi:10.1155/2010/901216
BibTeX
@article{Protzer2010,
author = {Protzer, U and Abken, H},
title = {Can Engineered “Designer” T Cells Outsmart Chronic Hepatitis B?},
journal = {Hepatitis Research and Treatment},
year = {2010},
doi = {10.1155/2010/901216}
}
EUVIMED